Dr. Daniel C. Liebler is Professor of Biochemistry, Pharmacology and Biomedical Informatics at the Vanderbilt University School of Medicine. He received a Ph.D. in Pharmacology from Vanderbilt while training in the laboratory of F. Peter Guengerich and did postdoctoral training in the laboratory of Donald J. Reed at Oregon State University.
From 1987-2003, Dr. Liebler served on the faculty of the Department of Pharmacology and Toxicology in the College of Pharmacy at the University of Arizona. Dr. Liebler’s research program focused for over 20 years on the interactions of chemicals with biological systems, including studies of antioxidant chemistry and its expression in biological systems, especially in skin, the development of methods to analyze modified and damaged proteins and the impact of protein damage by reactive chemicals. A major theme of this work has been the application of mass spectrometry technology to probe the chemistry-biology interface.
From 2006-2015, he was Director of the Jim Ayers Institute for Precancer Detection and Diagnosis at Vanderbilt. He led two National Cancer Institute-funded research programs focused on the application of proteomic technologies to develop new cancer diagnostics.
He is the founder and Chief Scientific Officer of Protypia, a biotechnology company that supports the development and use of new cancer therapeutics.